30-day Readmission After Operative Management of Adhesive Small Bowel Obstruction

30-day Readmission After Operative Management of Adhesive Small Bowel Obstruction Letters to the Editor Annals of Surgery  Volume 267, Number 3, March 2018 8. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant log-rank test). Survival of patients in margin University Hospital Carl Gustav Carus chemotherapy with gemcitabine and long-term group III was lower than that of patients in TU Dresden, Germany. outcomes among patients with resected pancre- margin group I (13 months, P < 0.001; log- Nuh.Rahbari@uniklinikum-dresden.de atic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–1481. rank test) and margin group II (P ¼ 0.08; log- 9. O?Reilly EM, Perelshteyn A, Jarnagin WR, et al. rank test). Collectively, these data confirm the A single-arm, nonrandomized phase II trial of results of our initial report. neoadjuvant gemcitabine and oxaliplatin in REFERENCES The topic of margin clearance and out- patients with resectable pancreas adenocarci- come has been controversial owing to the lack 1. Nitschke P, Volk A, Welsch T, et al. Impact of noma. Ann Surg. 2014;260:142–148. intraoperative re-resection to achieve R0 status on of uniform guidelines for the processing of 10. Ferrone CR, Marchegiani G, Hong TS, et al. survival in patients with pancreatic cancer: a Radiological and surgical implications of neo- surgical specimens, reporting of pathological single-center experience http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Surgery Wolters Kluwer Health

30-day Readmission After Operative Management of Adhesive Small Bowel Obstruction

Loading next page...
 
/lp/wolters_kluwer/30-day-readmission-after-operative-management-of-adhesive-small-bowel-jm3LyQHmCp
Publisher
Wolters Kluwer
Copyright
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
0003-4932
eISSN
1528-1140
D.O.I.
10.1097/SLA.0000000000002091
Publisher site
See Article on Publisher Site

Abstract

Letters to the Editor Annals of Surgery  Volume 267, Number 3, March 2018 8. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant log-rank test). Survival of patients in margin University Hospital Carl Gustav Carus chemotherapy with gemcitabine and long-term group III was lower than that of patients in TU Dresden, Germany. outcomes among patients with resected pancre- margin group I (13 months, P < 0.001; log- Nuh.Rahbari@uniklinikum-dresden.de atic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–1481. rank test) and margin group II (P ¼ 0.08; log- 9. O?Reilly EM, Perelshteyn A, Jarnagin WR, et al. rank test). Collectively, these data confirm the A single-arm, nonrandomized phase II trial of results of our initial report. neoadjuvant gemcitabine and oxaliplatin in REFERENCES The topic of margin clearance and out- patients with resectable pancreas adenocarci- come has been controversial owing to the lack 1. Nitschke P, Volk A, Welsch T, et al. Impact of noma. Ann Surg. 2014;260:142–148. intraoperative re-resection to achieve R0 status on of uniform guidelines for the processing of 10. Ferrone CR, Marchegiani G, Hong TS, et al. survival in patients with pancreatic cancer: a Radiological and surgical implications of neo- surgical specimens, reporting of pathological single-center experience

Journal

Annals of SurgeryWolters Kluwer Health

Published: Mar 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off